Invited speakers Named Lectures

Robert F. Furchgott lecture
Redox regulation of endothelial cell phenotypes: Role of LKB1-AMPK pathways

Professor Ming-Hui Zou bio
Research Science Center
Georgia State University
Atlanta, United States of America

John T. Shepherd lecture
Baroreceptor Reflex: Mechanisms of Mechanosensory Transduction, Adaptation and Modulation

Professor Mark Chapleau bio
Department of Internal Medicine
University of Iowa Carver College of Medicine
Iowa City, United States of America

Björn Folkow lecture
The physiological role of pericytes in the microcirculation

Professor Claire Peppiatt-Wildman bio
School of Sport and Exercise Sciences
University of Kent
Kent, United Kingdom

David F. Bohr Lecture
Signaling networks define vascular smooth
muscle cell function and plasticity

Professor Rhian M Touyz bio
British Heart Foundation (BHF) Chair in Cardiovascular Medicine
Director - Institute of Cardiovascular & Medical Sciences
University of Glasgow

Paul M. Vanhoutte Lecture
Lipocalin-2, a versatile drug target for
cardiovascular diseases

Dr. Yu Wang bio
Department of Pharmacology
University of Hong Kong
Hong Kong, China

Tudor Griffith Lecture (EDH)
Roles for EDH in the Initiation and
Modulation of Ascending Vasodilatation

Steven S. Segal, PhD bio
Medical Pharmacology and Physiology
University of Missouri
Columbia, United States of America

Ming-Hui Zou

is the eminent scholar in Georgia Research Alliance in Georgia, USA. Dr. Zou is the founding director, the Center of Molecular and Translational Medicine, and the Associate Vice President for Research, Georgia State University. Before he joined the Georgia State University, Dr. Zou was the George Lynn Cross Professor, Warren Endowed Chair in Diabetes Research, and Travis endowed Chair in Endocrinology in the University of Oklahoma Health Science Center, the Chief of Section of Molecular Medicine, and Vice Chair for Research in the Department of Medicine from 2005-2015.

Dr. Zou has been very productively working in the area of cardiovascular biology and diseases over 25 years. Dr. Zou was instrumental in examining the role of nitric oxide and oxidative stress in the regulation of blood flow and vascular function. He performed elegant, state of the art, studies to show that the selective modification of two key proteins, prosptacyclin synthase and endothelial nitric oxide synthase, is critical in the dysregulation of vessel function from nitric oxide and superoxide. Dr. Zou’s group was also the first to demonstrate that the AMP-activated kinase (AMPK), a key enzyme in the regulation of energy metabolism, obesity, diabetes, and cardiovascular diseases, functions as a redox sensor and modulator of oxidative stress in cardiovascular systems.

Furthermore, Dr. Zou and his group has systemically characterized the signaling pathways by which oxidants-induced LKB1-AMPK signaling axis in endothelial cells. Finally, Dr. Zou has systemically studies how LKB1 or AMPK becomes dysfunction in cardiovascular diseases and cancers and how dysfunctional LKB1/AMPK promotes cardiovascular disorders. Dr. Zou’s contributions in this area are important and his work represents outstanding breakthroughs research which has been recognized by many other investigators in the fields. An independent investigator of the National Institutes of Health and the Juvenile Diabetes Research Foundation International (JDRF) and an Established Investigator and National Scientist Development awardee of the American Heart Association and American Diabetes Association, Dr. Zou has used these (and many other awards) to make scientific observations in fields with great potential for immediate clinical relevance. He has served on several national study panels such as the National Science Foundation of China, the National Institutes of Health, American Diabetes Association, and American Heart Association.

He is also the Editor-in-chief for the journals “Diabetes, Metabolic Syndrome and Obesity” “World Journal of Diabetes” and has served the editorial boards of many prestigious journals including Nature Medicine, J. Exp. Med., J. Clin. Invest., Circulation、Circulation Research, ATVB, Diabetes, etc. He has published over 180 peer reviewed papers in highly impacted journals including Nature Medicine, J. Clin. Invest., Circulation, Circulation Research, Diabetes, Mol. Cell. Biol. Atherosclerosis, Vascular Biology, and Thrombosis, J. Biol. Chem., Hypertension. In 2008 he was elected to the American Society for Clinical Investigation, one of the US’ oldest honor societies of physician-scientists, membership in which reflects accomplishments by its members at an early stage in their careers.

Mark W. Chapleau

Mark W. Chapleau, PhD, FAHA, FAAS is Professor of Internal Medicine (Cardiovascular Medicine) & Molecular Physiology and Biophysics at the University of Iowa Carver College of Medicine and Research Health Science Specialist at the U.S. Department of Veterans Affairs Medical Center in Iowa City, Iowa, USA.

He received his PhD in Physiology from the Louisiana State University Health Sciences Center in New Orleans in 1985 and has been a faculty member at the University of Iowa since 1989.  Dr. Chapleau’s research focuses on neural mechanisms in cardiovascular regulation, with emphasis on mechanisms modulating excitability of baroreceptor and sympathetic neurons and baroreflex sensitivity in health and disease.

Current projects are investigating mechanisms of dysregulation in mouse models of hypertension, metabolic syndrome, hypertrophic cardiomyopathy and muscular dystrophy.  His research has been funded primarily by the U.S. National Institutes of Health, the U.S. Department of Veterans Affairs, and the American Heart Association.  Dr. Chapleau served as President of the Iowa Physiological Society (2003-2004) and the American Autonomic Society (2008-2010), Chair of the Neural Control and Autonomic Regulation (NCAR) section of the American Physiological Society (2009-2012), and Deputy Editor-in-Chief USA of the journal Experimental Physiology (2012-2016).  He has served on the editorial boards of several journals, including Clinical Autonomic Research and Current Hypertension Reviews currently.

Claire Peppiatt-Wildman

I graduated with a BSc (Hons) in Medical Biochemistry from Royal Holloway University of London in 1999 and a PhD in Cellular Physiology in 2002 from the University of Cambridge (Babraham Institute; supervised by Professor Sir Michael Berridge). Subsequently, I worked as a Research Associate at University College London (UCL) and St George’s Medical School University of London.

In 2007, I was awarded a significant Medical Research Council (MRC) Career Development Award (5 years) to conduct independent research in the Department of Physiology, UCL and then at the Royal Veterinary College. Since joining the UoK in 2012, I have worked as a Lecturer and then Senior Lecturer, whilst fulfilling the role of Director of Research and at Medway School of Pharmacy (MSoP). I currently lead the Urinary System Physiology Unit (in SSES), a research group originally founded in 2008 that is now internationally recognised for its significant contributions to the field. I have successfully supervised >20 PhD students to completion and >10 post-doctoral researchers.

My research is novel and drives advances in the field, I am considered a world-class researcher in urinary system physiology and regulation of blood flow, collaborating internationally (USA, Europe, and Australia) with multiple research centres. I have contributed to numerous high quality publications and reviews, highest IF 38.14 (Nature, on 2 occasions, 2x F1000 recommended) with >2527 citations. I regularly present at conferences worldwide upon invitation and have organised international conferences and research symposiums for many international meetings. To date, I have attracted >£2 million in research revenue, which has included significant investment from industry (Pfizer and Biogen Idec USA). My work is creating impact and has altered clinical practice (my research constituted one of MSoP’s impact case submissions in REF2014). I truly believe my research exemplifies a University of Kent research strategy: global research questions, tackled at a local level, with impact outside of academia – a strategy I passionately support and champion.

I completed my PGCHE qualification in 2014 (UoK) having created a strong track record of educational achievements related to teaching across many science disciplines. I have delivered basic science lectures to medical, pharmacy and veterinary students demonstrating an ability to align teaching with the learning objectives of a diverse range of BSc and MSc programmes. My scholarly interests align well to those of SSES. My research over the past 5-10 years has spanned the central nervous system, cardiovascular system, and urinary system, and thus I have a core knowledge of anatomy and physiology.

Rhian M Touyz

Professor Touyz is Director of the Institute of Cardiovascular & Medical Sciences and British Heart Foundation (BHF) Chair of Cardiovascular Medicine, Univ of Glasgow. She also directs the BHF Centre of Research Excellence in Vascular Science and Medicine. She is a clinician-scientist focusing on hypertension research, and honorary consultant at the Queen Elizabeth University Hospital. She was the Canada Research Chair in Hypertension at the Kidney Research Centre, Ottawa Hospital Research Institute, Univ of Ottawa, Canada until 2011 when she moved to Glasgow.

Dr Touyz received her BSc(Hons)(1980), MBBCh(1984), MSc(1986) and PhD(1992) in South Africa. She completed a post-doctoral fellowship at the Clinical Research Institute in Montreal. She has received numerous awards, including the Dahl Award (American Heart Association), Harriet Dustan Research Award (American Heart Association), Robert M. Berne Distinguished Award (American Physiological Society), RD Wright Award (BP Research Council, Australia), Irvine Page Award (ASH) and the Joan Mott Award (Physiology Society). She is a Fellow of the Academy of Medical Sciences.

Prof Touyz co-chaired the Canadian Hypertension Education Program for clinical guidelines. She is past President of the Canadian Hypertension Society, past Chair of the High Blood Pressure Research Council (AHA), and immediate-past President of the International Society of Hypertension. She is the in-coming President of the European Council for Cardiovascular Research. She is Editor-in-Chief of Clinical Science, Deputy Editor of Hypertension, and Associate Editor of Pharmacological Reviews. She has trained over 45 graduate students and published over 440 peer-reviewed papers. Her research interests include 1) molecular mechanisms, redox signaling and vascular biology of hypertension; 2) cardiovascular toxicity of anti-cancer drugs (VEGF inhibitors), 3) small vessel disease and complications of hypertension, and 4) vascular biology of cations and TRPM ion channels. She has a particular interest in translational research.

Yu Wang

Dr Yu Wang obtained her PhD in 2003 from the University of Auckland, New Zealand. She discovered the glycosylated forms of adiponectin and their hepatoprotective potentials. Since then, Dr Wang has continued the research on adiponectin for over 15 years and generated extensive publications with over 3000 citations. In 2008, she joined the Department of Pharmacology in the University of Hong Kong and worked together with Prof Paul M. Vanhoutte on endothelial senescence and vascular ageing.

Their research is focusing on SIRT1 in endothelial cells and has uncovered an important molecular signaling pathway that controls the vascular ageing process. Dr Wang has also pioneered the work on lipocalin-2 as a drug target for the treatment of obesity-related cardiovascular, metabolic and renal syndrome.

Steven S. Segal

Steve’s scientific interests originate in Exercise Physiology. His studies of oxygen consumption in exercising humans as a Master’s student at the University of California, Berkeley, led to studying skeletal muscle physiology as a doctoral student at the University of Michigan, where his research focused on muscle regeneration. For postdoctoral training, Steve studied the microcirculation at the University of Virginia, where propagated (conducted) vasodilation was first recognized in the hamster cheek pouch. During his initial years as faculty member in the Noll Physiological Research Center at Pennsylvania State University (1987-1992), Steve established his laboratory studying blood flow regulation in the microcirculation of skeletal muscle.

While a Fellow of the John B. Pierce Foundation Laboratory and Professor at Yale University (1992-2006), Steve’s research centered on understanding the nature of cell-to-cell communication in microvascular resistance networks in light of coordinating vasodilation and vasoconstriction among network branches. Since moving to the University of Missouri in 2006, Steve’s laboratory has developed novel approaches to studying electrical and calcium signaling in the resistance vasculature, with a continuing emphasis on skeletal muscle.

Returning to his roots as graduate student, Steve is applying his experience as a microcirculation guy to investigate how the microcirculation recovers – as well as the role that it plays – during skeletal muscle regeneration following injury.